Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(33.3%)
N/A
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 4(1)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03196050Not ApplicableCompleted

Telemonitoring of Geriatric Cancer Patients Using Handheld Devices

Role: collaborator

NCT00764036Phase 1Completed

Study of Artesunate in Metastatic Breast Cancer

Role: collaborator

NCT00149097Completed

Role of the Autonomic Nervous System in HIV-Lipodystrophy

Role: collaborator

NCT00160901Phase 4Completed

Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer

Role: collaborator

All 4 trials loaded